Lowest Price Guaranteed
Slides
222
Last Updated
June 2026
View Count
23462
The global allogeneic cell therapy market valued at USD 50.0 million in 2025, is projected to grow to USD 52.4 million in 2026 and USD 1,629.6 million by 2035, representing a CAGR of 46.5% during the forecast period 2026 to 2035.
 |
To learn more about this report, request a free sample copy
Allogeneic cell therapies refer to off-the-shelf therapies that are isolated from donor tissues (such as cord blood and bone marrow), processed ex vivo in the labs and then administered into patients / cryopreserved in a cell bank. Since these therapies are manufactured in advance, they are readily available and eliminate the need for individualized production for every patient. Owing to their various benefits, such as improved and consistent product quality (due to rigorous quality control measures taken during processing), reduced cost (due to centralized manufacturing process) and flexibility in approaching the same donor or choosing a different donor (in case the patient requires another course of the treatment), allogeneic cell therapies have gained significant traction in the healthcare industry. Further, recent advancements in gene editing technologies, such as CRISPR/Cas9, have opened up new possibilities for allogeneic cell therapies by enabling precise genetic modifications in the donor cells in order to enhance their therapeutic properties and reduce the risk of immune rejection.
 |
 |
 |
Over the past few years, a number of allogeneic cell therapies targeting a myriad of disorders, including hematological malignancies (such as multiple myeloma, leukemia), post-transplant lymphoproliferative disorders (PTLD), neurological disorders, musculoskeletal disorders and autoimmune / inflammatory disorders, have received approval from various regulatory authorities, globally. In December 2022, the European Commission approved the first allogeneic T-cell therapy, namely Ebvallo, (developed by Atara Biotherapeutics) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease. In addition, the FDA approved an allogenic mesenchymal stem cell therapy, Osteocel® Plus (developed by NuVasive), for the treatment of degenerative disc disease. Driven by the continuous efforts of both industry and non-industry players, rising prevalence of chronic diseases and non-malignant disorders, and challenges associated with production of autologous cell therapies, the global allogeneic cell therapies market is likely to witness substantial market growth during the forecast period.
Based on the type of cell therapy, the market is segmented into virus-specific T-Cell therapy, stem cell therapy, and regulatory T-Cell therapy.
According to our analysis, the stem cell therapy segment accounts for 90% of the overall market share. This is driven by the extensive utilization of hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs), which have established standards of care for refractory blood cancers, orthopedic conditions, and wound-healing applications. Further, the high volume of bone marrow and umbilical cord-derived products are currently in Phase III clinical trial studies or early commercialization for chronic diseases, such as diabetes and leukemia. This provides a robust and scalable foundation for sustained institutional investment and hospital procurement.
In the coming year, regulatory T-cells (Tregs) therapy segment is projected to grow at a relatively faster pace, witnessing a high CAGR of 23% till 2035. This rapid expansion is primarily attributed to the emergence of Tregs as a transformative therapeutic modality for autoimmune disorders and organ transplant rejection. As clinical pipelines expand, this segment is offering opportunities to pharmaceuticals for collaborations, therapies innovation and mergers.
Based on source of cell, the market is segmented into bone marrow / matrix, peripheral blood, placenta, adipose tissue, umbilical cord, placenta and others.
According to our market projection, the bone marrow / matrix segment holds the highest share (70%) of the overall market. This dominance is likely to be the result of the long-standing clinical validation of bone marrow as a primary source for hematopoietic stem cells, which are essential for treating various hematological malignancies. Moreover, the established bone marrow-derived products are already integrated into hospital treatment protocols and large-scale clinical trials. This ensures that this segment remains the most prominent due to the widespread adopted source for allogeneic cell therapies.
In the future, the adipose tissue segment is projected to expand at a relatively faster pace, witnessing a high CAGR of 25% through 2035. This growth is primarily attributed to the shift toward "off-the-shelf" allogeneic products, where the umbilical cord offers high-yield, non-invasively collected cells with lower immunogenicity. Simultaneously, the rising demand for mesenchymal stem cells (MSCs) for regenerative medicine and autoimmune disorders is fueling the growth of adipose tissue sources as it provide cost-effective scale-up characteristics and manufacturing flexibility.
Based on the target indication, the market is segmented into infectious disease, chronic heart failure, Crohn’s disease, ischemic stroke, hematological cancer, bone disorder, critical limb ischemia, graft versus host disease (GvHD), Duchenne muscular dystrophy, epidermolysis bullosa, diabetic foot ulcer, and other indications.
According to our allogeneic cell therapy market forecast, the chronic heart failure segments currently hold the highest shares (31%) of the overall market. This dominance is driven by the high clinical demand for regenerative solutions in cardiovascular care and the well-established use of allogeneic stem cell transplants as a curative standard for leukemia and lymphoma. In addition, the presence of a robust late-stage clinical pipeline for these indications, combined with standardized hospital protocols, ensures they remain the primary revenue drivers for institutional buyers and healthcare providers.
Conversely, the epidermolysis bullosa segment is likely to show robust growth, witnessing a high CAGR of 27% during the forecast period till 2035. This unprecedented growth is due to the high unmet medical need and the breakthrough status of allogeneic "off-the-shelf" products in treating rare genetic skin disorders and post-transplant viral infections. As pharmaceutical companies will move towards high-growth niche indications with orphan drug designations and accelerated regulatory pathways, epidermolysis bullosa will attract pharmaceutical companies for research and investments.
On the basis of therapeutic area, the market is segmented into post-transplant infections, cardiovascular disorders, autoimmune / inflammatory disorders, cerebrovascular disorders, musculoskeletal disorders, oncological disorders, neurological disorders, genetic disorders, and other disorders.
According to our allogeneic cell therapy market report, the cardiovascular disorders segment currently lead the market with 31% of the overall revenue share. This highest share is due to the increasing usage of allogeneic therapies and regenerative solutions in chronic heart failure.
On the other hand, the autoimmune / inflammatory disorders segment will grow at a higher CAGR of 25% during the forecast period. This rapid growth is primarily due to increasing number of specialized cell therapies entering clinical pipelines to address high unmet medical needs in chronic inflammation. In addition, the rising focus on personalized medicines and orphan drugs within these areas is expected to drive the growth as flexible, innovative treatment modalities gain regulatory momentum.
Based on the geographical regions, the global market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.
According to our analysis, North America currently holds the highest share (75%) of the overall market. This largest share is due the presence of a well-established healthcare infrastructure, high adoption of advanced regenerative medicines, and a robust ecosystem of biopharmaceutical companies dedicated to allogeneic cell therapy innovation. Further, the availability of substantial funding for research and development, alongside favorable regulatory frameworks, ensures that the region remains the primary revenue driver for global market participants.
While North America dominates the market, Europe region is projected to expand at a higher CAGR till 2035. This rapid growth is primarily attributed to the region’s emerging biopharma infrastructure, favorable regulatory policies, and the presence of cost-effective manufacturing capabilities. Moreover, rising government initiatives and a growing number of clinical trials for "off-the-shelf" therapies are fueling growth of the market in the region
The "Allogeneic Cell Therapy Market: Industry Trends and Global Forecasts, till 2035" market report features an extensive study of the current market landscape, market size and future opportunities for the allogenic cell therapy developers, during the given forecast period. Further, the report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the allogeneic therapy market report are briefly discussed below.
 |
 |
 |
Allogeneic cell therapy and autologous cell therapy are two distinct approaches in regenerative medicine market. In autologous cell therapy, the cells are derived from the patient's own body, processed ex-vivo and reintroduced into the same patient; this personalized approach ensures compatibility and minimizes the risk of immune rejection. However, these therapies require a longer production time, as each patient's cells need to be individually processed. On the other hand, allogeneic cell therapy involves the use of cells from a healthy donor; these collected donor cells might be given directly to a genetically similar patient or added to a cell bank. Allogeneic cell therapy has various advantages, including immediate accessibility, scalability and cost-effectiveness, however, it may involve the risk of immune rejection.
Allogeneic cell therapy market landscape features the presence of close to 195 large, mid-sized and small companies developing allogeneic cell therapies, for a wide range of indications. It is worth highlighting that over 470 allogenic cell therapies are currently being evaluated in different preclinical / clinical stages, either as monotherapies or in combination with other drugs. In April 2023, Gamida Cell received approval from the FDA for its umbilical cord blood-derived, allogeneic stem cell therapy, Omisirge® (omidubicel-onlv); the therapy is used to treat patients with hematologic malignancies. The growing demand for novel allogeneic cell therapies, approvals from various regulatory bodies and continuous advancements in cell therapy manufacturing process, are expected to drive the allogeneic cell therapies market growth during the forecast period.
Over the years, companies involved in the development of allogeneic cell therapies have made significant efforts to conduct clinical trials for evaluating the efficacy of allogeneic cell therapies, for the treatment of various disorders, including infectious diseases (adenovirus infection, coronavirus infection and cytomegalovirus infection), neurological disorders (autism, bipolar depression, Parkinson’s disease, stroke) and oncological disorders (acute myeloid leukemia, biliary tract cancer, breast cancer and multiple myeloma). Over 365 clinical trials have been registered across different geographical regions to evaluate various allogenic cell therapies. Of these trials, majority (~180) were registered in North America and maximum number of patients (9,300) were observed to be enrolled in clinical trials conducted in North America, accounting for about 55% of the overall enrollment. It is worth mentioning that Fundamenta Therapeutics is conducting the maximum number of trials in this industry for different types of cancers, such as acute lymphoblastic leukemia, acute lymphoblastic lymphoma and non-Hodgkin’s lymphoma. In addition, an allogeneic CAR T cell therapy, ALLO-715 (developed by Allogene) for the treatment of relapsed / refractory multiple myeloma has demonstrated positive results in the Phase I clinical trials.
A number of allogeneic cell therapies are likely to enter clinical trials in the current year, with the drug developers receiving FDA clearance. In February 2024, FDA granted clearance to the IND application for ACE2016, an allogeneic γδ2 T-cell therapy for the treatment of patients with solid tumors that express epidermal growth factor receptor (EGFR). In April 2024, Tr1X received the FDA clearance of first investigational new drug application for TRX103, an allogeneic regulatory T-Cell therapy for the prevention of Graft versus Host Disease (GvHD) in patients undergoing HLA-mismatched hematopoietic stem cell transplantation (HSCT).
Several stakeholders have been forging alliances with other industry / non-industry players for the development of allogeneic cell therapies. It is worth highlighting that, since 2019, over 90 strategic partnerships have been established in the allogeneic cell therapy market. Majority of such deals are focused on research and development, product / technology licensing, and development and commercialization of allogenic cell therapies. In March 2023, Tessa Therapeutics entered into a research and development agreement with US National Cancer Institute for Tessa’s allogeneic CD30.CAR-modified Epstein-Barr virus-specific T-cell therapy, TT11X, useful in the treatment of non-Hodgkin’s lymphoma. In January 2022, Allogene Therapeutics signed a licensing agreement with Antion Biosciences for the latter company’s miRNA technology (miCAR™) in order to advance multiplex gene silencing tool (useful in the development of innovative allogeneic CAR T cell therapy).
In March 2024, Allogene Therapeutics and Arbor Biotechnologies, entered into a strategic partnership agreement in order to use Arbor’s proprietary CRISPR gene-editing technology in Allogene’s next generation AlloCAR T platform for the treatment of autoimmune disease (AID).
The growing interest in allogeneic cell therapy market can be validated by the fact that in the past four years, close to USD 8.8 billion has been invested by several investors based across the globe, in companies engaged in the development of allogeneic cell therapies. It is worth noting that, majority of the funds have been raised through venture rounds. In terms of the funding amount raised, Legend Biotech raised the maximum funding amount (USD 487.3 million) through initial public offering. In December 2022, Gamida Cell announced the closing of a convertible term loan of USD 25 million with Highbridge Capital Management; the funding is planned to be used to advance the company’s allogeneic NK cell therapy pipeline.
The global allogeneic cell therapy market is estimated to be worth USD 52.4 million in 2026. Driven by the increasing need for novel allogenic cell therapies, along with growing development pipeline and encouraging clinical trial results, the allogenic cell therapies market is anticipated to grow at a CAGR of 46.5% during the forecast period. Specifically, in terms of target disease indication, the market is anticipated to be driven by allogeneic cell therapies being developed for the treatment of lymphoma and leukemia.
Examples of the key allogeneic cell therapy companies (based on number of products under development; the complete list of players is available in the full report) include Artiva Biotherapeutics, Allogene Therapeutics, Atara Biotherapeutics, Cellenkos, Cell2Cure, Celularity, Cellular Biomedicine Group, CHABiotech, CRISPR Therapeutics, Fate Therapeutics, Fundamenta Therapeutics, GC Cell, Hope Biosciences, Immunity Bio, Mesoblast, Nanjing Bioheng Biotech, Orca Bio, Pluristem Therapeutics, Poseida Therapeutics and Stemedica Cell Technologies. This market report also includes an easily searchable excel database of all the allogeneic therapy companies (developers) worldwide.
Several recent developments have taken place in the field of allogeneic cell therapy. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The market report presents an in-depth analysis of the various firms / organizations that are engaged in the allogeneic cell therapy market, across different segments, as defined in the below table:
| Key Report Attributes | Details | |
| Forecast Period |
Till 2035 |
|
|
Market Size 2026 |
USD 52.4 Million |
|
|
Market Size 2035 |
USD 1,629.6 Million |
|
|
CAGR |
46.5% |
|
|
Type of Cell Therapy |
|
|
|
Source of Cell |
|
|
|
Target Indication |
|
|
|
Therapeutic Area |
|
|
|
Key Geographical Regions |
|
|
|
Customization Scope |
|
|
|
Excel Data Packs (Complimentary) |
|
|
 |
 |
 |
The research report presents an in-depth analysis, highlighting the capabilities of various stakeholders in this market, across different geographies. Amongst other elements, the market report includes:
One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of the allogeneic cell therapies market, over the forecast period. We have provided informed estimates on the likely evolution of the market for the forecast period, till 2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as type of cell therapy (virus-specific T-cell, stem cell and regulatory T-cell), source of cell (peripheral blood, bone marrow, umbilical cord blood, adipose tissue and placenta), target indication (Bone Disorder, Critical Limb Ischemia, Crohn’s Disease, Diabetic Foot Ulcer, Graft versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndrome, Cytomegalovirus Infection, Others), therapeutic area (oncological disorders, neurological disorders, musculoskeletal disorders, autoimmune / inflammatory disorders, post-transplant infections), and key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s evolution.
The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with some of the key industry stakeholders.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.